PapersFlow Research Brief
Hepatitis C virus research
Research Guide
What is Hepatitis C virus research?
Hepatitis C virus research is the scientific study of the epidemiology, antiviral treatments, genetic variations affecting viral clearance, immune responses, liver disease outcomes, and comorbidities associated with hepatitis C virus infection.
The field encompasses 137,668 published works on topics including antiviral therapy with drugs like peginterferon and ribavirin, noninvasive fibrosis prediction models, and genetic predictors of treatment success. Fried et al. (2002) in "Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection" demonstrated higher sustained virologic responses with combination therapy compared to peginterferon alone. Manns et al. (2001) in "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial" showed peginterferon alfa-2b plus ribavirin achieved superior efficacy over standard interferon plus ribavirin.
Topic Hierarchy
Research Sub-Topics
Direct-Acting Antiviral Therapy for HCV
This sub-topic assesses efficacy, resistance profiles, and pan-genotypic regimens of DAAs like sofosbuvir in diverse patient populations. Researchers study real-world outcomes and retreatment strategies.
IL28B Genetic Variation in HCV Clearance
This sub-topic investigates single nucleotide polymorphisms in IFNL3/IL28B and their role in spontaneous clearance and interferon response. Genome-wide studies identify predictors of treatment success.
HCV Fibrosis Assessment Noninvasive
This sub-topic develops and validates biomarkers like FIB-4, APRI, and elastography for staging liver fibrosis without biopsy. Researchers correlate indices with histological progression in HCV cohorts.
Global HCV Epidemiology
This sub-topic maps prevalence, incidence, and transmission routes including iatrogenic and injection drug use worldwide. Modeling studies forecast burden and intervention impacts toward elimination.
HCV-HIV Coinfection Outcomes
This sub-topic examines accelerated fibrosis, treatment responses, and liver-related mortality in HIV/HCV dually infected patients. Studies evaluate integrated care models and DAA safety.
Why It Matters
Hepatitis C virus research has directly informed clinical treatments that achieve sustained virologic responses in chronic infection patients, as shown by Fried et al. (2002) where peginterferon alfa-2a plus ribavirin yielded significantly higher response rates than peginterferon alone, with 6389 citations reflecting its impact. Noninvasive indices developed by Wai et al. (2003) in "A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C" enable fibrosis staging without biopsy risks, aiding management of 170 million chronic carriers worldwide as noted by Ge et al. (2009). Genetic studies like Ge et al. (2009) in "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance" identified IL28B variants predicting clearance, guiding personalized therapy. Recent U.S. initiatives include HHS's $100M pilot funding for HCV prevention and treatment in substance use disorder patients and SAMHSA's $98M for elimination pilots, targeting rural transmission networks.
Reading Guide
Where to Start
"Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection" by Fried et al. (2002), as it provides foundational evidence on combination therapy efficacy with 6389 citations and clear comparison to monotherapy.
Key Papers Explained
Fried et al. (2002) "Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection" and Manns et al. (2001) "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial" established peginterferon-ribavirin combinations as superior standards, with 6389 and 6043 citations. Ge et al. (2009) "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance" built on these by identifying IL28B genetics predicting response to that regimen. Wai et al. (2003) "A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C" and Sterling et al. (2006) "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection" extended clinical utility with fibrosis tools. Bédossa and Poynard (1996) "An Algorithm for the Grading of Activity in Chronic Hepatitis C" provides the histological basis for staging.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Preprints highlight highly replicating HCV variants in immunosuppressed patients via NS5A mutations, live-attenuated vaccines for hepacivirus models, and genomic surveillance of rural U.S. transmission. News covers $100M HHS and $98M SAMHSA funding for elimination pilots targeting substance use disorder populations, plus NIAID/NIBIB efforts on rapid point-of-care diagnostics.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C V... | 2002 | New England Journal of... | 6.4K | ✕ |
| 2 | Peginterferon alfa-2b plus ribavirin compared with interferon ... | 2001 | The Lancet | 6.0K | ✕ |
| 3 | Hepatocellular carcinoma | 2021 | Nature Reviews Disease... | 6.0K | ✓ |
| 4 | EASL 2017 Clinical Practice Guidelines on the management of he... | 2017 | Journal of Hepatology | 5.3K | ✕ |
| 5 | The HCV Life Cycle: In vitro Tissue Culture Systems and Therap... | 2014 | Digestive Diseases | 4.9K | ✓ |
| 6 | Development of a simple noninvasive index to predict significa... | 2006 | Hepatology | 4.6K | ✓ |
| 7 | A Simple Noninvasive Index Can Predict Both Significant Fibros... | 2003 | Hepatology | 4.3K | ✓ |
| 8 | Update on prevention, diagnosis, and treatment of chronic hepa... | 2018 | Hepatology | 4.1K | ✓ |
| 9 | An Algorithm for the Grading of Activity in Chronic Hepatitis C | 1996 | Hepatology | 4.0K | ✓ |
| 10 | Genetic variation in IL28B predicts hepatitis C treatment-indu... | 2009 | Nature | 3.5K | ✓ |
In the News
HHS Announces $100M in Pilot Funding Opportunity to ...
The U.S. Department of Health and Human Services (HHS) has announced a $100M pilot funding opportunity to prevent, test for, treat, and cure Hepatitis C (HCV) in individuals with substance use diso...
SAMHSA Awards $98M for Hepatitis C Elimination Initiative Pilot
* The Interagency Coordinating Committee on the Prevention of Underage Drinking * About ICCPUD * Contributing Agencies * Reports to Congress * Alcohol Intake and Health Study
Advancing Development of Rapid Point-of-Care Hepatitis C Virus Diagnostics
The purpose of this Notice of Special Interest is to announce that the National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Biomedical Imaging and Bioengineering ...
Closing the gap in HCV care: strategic collaboration ...
Increased funding for hepatitis C virus (HCV) research and care delivery is needed to support effective programs for vulnerable communities and meet the WHO 2030 targets for HCV elimination. Strate...
Hepatitis C Elimination Initiative Pilot
- State Opioid Treatment Authorities - 42 CFR Part 8 Final Rule - Table of Changes - FAQs - 42 CFR Part 8 Regulation Video Series
Code & Tools
HCV-GLUE is a sequence-oriented resource for comparative genomic analysis of hepatitis C virus (HCV), developed using the** GLUE **software framework.
HCV-NABS ( **H** epatitis **C** **V** irus -- **N** eutralising **A** nti **B** odie **S**) is a linked dataset and set of analysis scripts for ana...
## About Genomic analysis pipeline for genotyping of Hepatitis C Virus ### Topics next-generation-sequencing microbial-genomics data-analysis-p...
Genotyping tool to assess HCV genetic diversity (genotype and subtype) from NGS data. ### Resources Readme ### License GPL-3.0 license Ac...
significant to the rise and fall of the infection. The model is written in Python, and we implement the NetworkX library to graph and modify the un...
Recent Preprints
Highly replicating hepatitis C virus variants emerge in immunosuppressed patients causing severe disease
Hepatitis C virus (HCV) exists as a heterogenous quasispecies, but the phenotypic consequences of viral variability are widely unexplored. Here we identify a replication enhancing domain (ReED) in ...
Hepatitis C virus articles from across Nature Portfolio
Hepatitis C virus (HCV) variability and its phenotypic consequences aren’t well studied in relation to viral replication fitness and disease severity. Here, the authors identify a replication-enhan...
Design and nonviral delivery of live attenuated vaccine to prevent chronic hepatitis C virus-like infection
An effective vaccine for the hepatitis C virus (HCV) remains an unmet medical need. There is no animal model for assessing HCV vaccines; however, rodent hepacivirus (RHV) infection in laboratory ra...
Targets of protective immunity and opportunities in hepatitis C virus vaccine development
Hepatitis C virus (HCV) remains a serious global health burden that affects nearly 50 million people worldwide. Despite the availability of highly effective direct-acting antiviral drugs, the lack ...
Genomic surveillance uncovers regional variation in HCV transmission networks in rural United States
Hepatitis C virus (HCV) remains a public health concern in the United States, particularly in rural communities where the opioid epidemic accelerates transmission among people who use drugs (PWUD)....
Latest Developments
Recent developments in Hepatitis C virus research include the discovery of macrocycle-based PROTACs that selectively degrade cyclophilin A, showing potent antiviral activity against HCV (nature.com), advancements in vaccine development with a live-attenuated vaccine demonstrating protective T cell responses in rats (nature.com), and ongoing clinical trials evaluating new antiviral regimens (mayo.edu). Additionally, studies have identified highly replicating HCV variants in immunosuppressed patients causing severe disease (nature.com), and efforts continue toward hepatitis C elimination, including legislation like the Cure Hepatitis C Act of 2025 (aasld.org). The most recent research as of February 2026 highlights these promising therapeutic and preventive strategies (nature.com).
Sources
Frequently Asked Questions
What treatments were compared for chronic hepatitis C?
Fried et al. (2002) compared peginterferon alfa-2a plus ribavirin to peginterferon alfa-2a alone, finding the combination produced significantly higher sustained virologic responses. Manns et al. (2001) showed peginterferon alfa-2b plus ribavirin outperformed interferon alfa-2b plus ribavirin in initial treatment.
How is liver fibrosis predicted noninvasively in HCV patients?
Wai et al. (2003) developed a simple index using routine tests to predict both significant fibrosis and cirrhosis in chronic hepatitis C patients. Sterling et al. (2006) created a noninvasive index specifically for HIV/HCV coinfected patients to assess fibrosis severity.
What genetic factor predicts HCV treatment success?
Ge et al. (2009) identified genetic variation in IL28B as a predictor of hepatitis C treatment-induced viral clearance in patients on peginterferon plus ribavirin. This affects response in chronic infections impacting 170 million people globally.
What is the HCV life cycle focus in research?
Khan and Whidby (2014) in "The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets" describe HCV as a variable plus-strand RNA virus with six genotypes differing by over 30% at nucleotide level, enabling immune evasion. The work covers in vitro systems and therapeutic targets.
How is histological activity graded in chronic hepatitis C?
Bédossa and Poynard (1996) proposed an algorithm generating a single activity score from basic necroinflammatory lesions for grading activity in chronic hepatitis C. This reflects global assessment of liver pathology.
What tools support HCV genomic analysis?
HCV-GLUE provides a sequence-oriented resource for comparative genomics of hepatitis C virus. GitHub tools like hcv-nf and HCVgenotool enable genotyping from NGS data, while HCV-NABS analyzes neutralizing antibody binding sites.
Open Research Questions
- ? How do highly replicating HCV variants with replication-enhancing domains in NS5A emerge in immunosuppressed patients and contribute to severe disease?
- ? Can live-attenuated vaccines designed for rodent hepacivirus prevent chronic HCV-like infections in animal models?
- ? What are the primary targets of protective immunity for advancing HCV vaccine development?
- ? How does regional genomic variation in HCV transmission networks affect rural U.S. communities with high opioid use?
- ? What phenotypic consequences arise from HCV quasispecies variability in replication fitness and disease outcomes?
Recent Trends
Preprints from late 2024 to early 2025 identify replication-enhancing domains in NS5A driving severe disease in immunosuppressed patients and regional HCV transmission variations in rural U.S. via genomic surveillance of 692 antibody-positive samples.
Vaccine efforts include live-attenuated designs for rodent hepacivirus and immunity targets amid 50 million global cases.
U.S. funding surged with HHS $100M pilot on July 28, 2025, for HCV in substance use disorder patients and SAMHSA $98M on September 24, 2025, for elimination initiatives.
Research Hepatitis C virus research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Hepatitis C virus research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers